La Jolla Pharmaceutical Company

NasdaqCM:LJPC Stock Report

Market Cap: US$155.1m

La Jolla Pharmaceutical Balance Sheet Health

Financial Health criteria checks 0/6

La Jolla Pharmaceutical has a total shareholder equity of $-69.5M and total debt of $124.5M, which brings its debt-to-equity ratio to -179.3%. Its total assets and total liabilities are $99.4M and $168.8M respectively.

Key information

-179.3%

Debt to equity ratio

US$124.54m

Debt

Interest coverage ration/a
CashUS$48.66m
Equity-US$69.47m
Total liabilitiesUS$168.83m
Total assetsUS$99.37m

Recent financial health updates

No updates

Recent updates

Innoviva to acquire La Jolla Pharma for $149M including debt

Jul 11

We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Nov 11
We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Our Take On La Jolla Pharmaceutical Company

Jul 02

La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue

May 07

La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Mar 11
La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Feb 11
Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Jan 16
Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

La Jolla Pharmaceutical rallies on exclusive licensing agreement with PAION

Jan 12

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Jan 05
Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

Dec 09
Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue

Nov 09

Financial Position Analysis

Short Term Liabilities: LJPC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LJPC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LJPC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LJPC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: LJPC's debt is not well covered by operating cash flow (10.5%).

Interest Coverage: Insufficient data to determine if LJPC's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.